Татьяна Евгеньевна Блинова
Research Subjects
Татьяна Евгеньевна Блинова has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Olga V. Shushpanova
Mental Health Research Center
13 shared publications - Elena E. Balakireva
Belgorod State National Research University
10 shared publications - Svetlana G. Nikitina
FSBSI Mental Health Research Centre
9 shared publications - Антон Владиславович Куликов
FSBSI Mental Health Research Centre
8 shared publications - Наталья Сергеевна Шалина
FSBSI Mental Health Research Centre
8 shared publications - Alexey A. Koval-Zaitsev
Mental Health Research Center
6 shared publications
Latest Publications
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Increased nervous excitability, anxiety, and sleep disorders in childhood — the role of multicomponent low-dose medications
Anxiety, emotional excitability, and sleep disturbances are common in pediatric populations, often emerging during stressful periods such as chronic family conflict, parental divorce, initial socialization in kindergarten, and the beginning of formal schooling. These conditions are frequently linked to autonomic nervous system (ANS) dysfunction. During such periods, nervous system instability impairs stress adaptation and may lead to neurotic reactions. Chronic stress and anxiety can trigger neuroinflammatory processes, which further intensify anxiety and ANS dysfunction. Clinically, these mechanisms present as autonomic disorders, including various types of pain, sleep disturbances, increased anxiety, emotional instability, and behavioral disorders. Higher rates of anxiety and insomnia are observed in children with attention deficit hyperactivity disorder, autism spectrum disorders, and other psychiatric conditions. Early intervention that combines psychological correction with safe pharmacotherapy is critical. Given the limitations of psychopharmacological treatments in pediatric patients, standardized phytotherapy is commonly employed, particularly low-dose, multicomponent medications such as Nervoheel and Neurexan. A review of current studies suggests that Neurexan and Nervoheel are effective in managing neurotic anxiety, fears, and sleep disorders in children, and may also improve ANS dysfunction associated with emotional instability, irritability, fatigue, and senestalgia.
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Increased nervous excitability, anxiety, and sleep disorders in childhood — the role of multicomponent low-dose medications
Anxiety, emotional excitability, and sleep disturbances are common in pediatric populations, often emerging during stressful periods such as chronic family conflict, parental divorce, initial socialization in kindergarten, and the beginning of formal schooling. These conditions are frequently linked to autonomic nervous system (ANS) dysfunction. During such periods, nervous system instability impairs stress adaptation and may lead to neurotic reactions. Chronic stress and anxiety can trigger neuroinflammatory processes, which further intensify anxiety and ANS dysfunction. Clinically, these mechanisms present as autonomic disorders, including various types of pain, sleep disturbances, increased anxiety, emotional instability, and behavioral disorders. Higher rates of anxiety and insomnia are observed in children with attention deficit hyperactivity disorder, autism spectrum disorders, and other psychiatric conditions. Early intervention that combines psychological correction with safe pharmacotherapy is critical. Given the limitations of psychopharmacological treatments in pediatric patients, standardized phytotherapy is commonly employed, particularly low-dose, multicomponent medications such as Nervoheel and Neurexan. A review of current studies suggests that Neurexan and Nervoheel are effective in managing neurotic anxiety, fears, and sleep disorders in children, and may also improve ANS dysfunction associated with emotional instability, irritability, fatigue, and senestalgia.
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Obsessive-compulsive disorder in the context of schizotypal disorder among children and adolescents
This review analyzes obsessive-compulsive disorder (OCD) in the context of schizotypal disorder (STD) among children and adolescents. Recent studies indicate that children with schizophrenia spectrum disorders have an elevated risk of developing obsessive-compulsive symptoms. Additionally, comorbidity of OCD with schizophrenia or STD is linked to a more severe clinical trajectory and lower responsiveness to treatment. The manifestation of OCD in patients with STD diverges from classical presentations, requiring comprehensive diagnostic approaches to elucidate etiological mechanisms, assess prognosis, and guide effective interventions. The literature emphasizes both the importance and the ongoing underdevelopment of this area. This issue lies at the intersection of two principal challenges in contemporary psychiatry: the nosological distinction between obsessive-compulsive and schizophrenia spectrum disorders, and the development of precise diagnostic and therapeutic strategies within the psychotic disorder continuum. To date, no studies have examined correlations between STD and OCD symptoms using validated psychometric tools, such as the Children’s Yale—Brown Obsessive—Compulsive Scale (CY-BOCS) and the Schizotypal Personality Questionnaire (SPQ). Evidence of the adverse effects of comorbid symptoms on social functioning and prognosis further highlights the clinical relevance of this topic for improving quality of life in these patients.
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Obsessive-compulsive disorder in the context of schizotypal disorder among children and adolescents
This review analyzes obsessive-compulsive disorder (OCD) in the context of schizotypal disorder (STD) among children and adolescents. Recent studies indicate that children with schizophrenia spectrum disorders have an elevated risk of developing obsessive-compulsive symptoms. Additionally, comorbidity of OCD with schizophrenia or STD is linked to a more severe clinical trajectory and lower responsiveness to treatment. The manifestation of OCD in patients with STD diverges from classical presentations, requiring comprehensive diagnostic approaches to elucidate etiological mechanisms, assess prognosis, and guide effective interventions. The literature emphasizes both the importance and the ongoing underdevelopment of this area. This issue lies at the intersection of two principal challenges in contemporary psychiatry: the nosological distinction between obsessive-compulsive and schizophrenia spectrum disorders, and the development of precise diagnostic and therapeutic strategies within the psychotic disorder continuum. To date, no studies have examined correlations between STD and OCD symptoms using validated psychometric tools, such as the Children’s Yale—Brown Obsessive—Compulsive Scale (CY-BOCS) and the Schizotypal Personality Questionnaire (SPQ). Evidence of the adverse effects of comorbid symptoms on social functioning and prognosis further highlights the clinical relevance of this topic for improving quality of life in these patients.
- 5 March 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (2) , 83-91
Clinical experience with melatonin and memantine combination (Miladean) in children with cognitive and behavioral impairments
An open-label, single-arm pilot study evaluated the efficacy of the combined melatonin and memantine preparation (Miladean) as add-on therapy in 20 children and adolescents (aged 8—15 years) with cognitive and behavioral impairments within hyperkinetic conduct disorder (F90.1, n=7), schizotypal disorder (F21, n=10), and schizophrenia (F20, n=3). All patients received stable background therapy, to which Miladean was added (2 tablets sublingually at bedtime) for 8 weeks. Cognitive tests (Raven’s Progressive Matrices, Stroop test, computerized Go/No-Go task), sleep quality questionnaire (modified Spiegel scale), and ADHD symptom scales (SNAP-IV) were used to assess outcomes. The drug demonstrated a favorable safety and tolerability profile. A statistically significant reduction in symptoms of inattention and hyperactivity-impulsivity on the SNAP-IV scale (p<0.001), improved sleep quality (p=0.002), and increased reaction speed in the Go/No-Go task (p=0.001—0.033) were observed. A trend towards improved performance on the intelligence test (Raven’s Progressive Matrices, p=0.067—0.077) was noted. The preliminary data obtained at this study indicate the potential efficacy of Miladean in correcting cognitive and behavioral impairments in children across various diagnostic categories and justify conducting further double-blind, placebo-controlled studies.
- 5 March 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (2) , 83-91
Clinical experience with melatonin and memantine combination (Miladean) in children with cognitive and behavioral impairments
An open-label, single-arm pilot study evaluated the efficacy of the combined melatonin and memantine preparation (Miladean) as add-on therapy in 20 children and adolescents (aged 8—15 years) with cognitive and behavioral impairments within hyperkinetic conduct disorder (F90.1, n=7), schizotypal disorder (F21, n=10), and schizophrenia (F20, n=3). All patients received stable background therapy, to which Miladean was added (2 tablets sublingually at bedtime) for 8 weeks. Cognitive tests (Raven’s Progressive Matrices, Stroop test, computerized Go/No-Go task), sleep quality questionnaire (modified Spiegel scale), and ADHD symptom scales (SNAP-IV) were used to assess outcomes. The drug demonstrated a favorable safety and tolerability profile. A statistically significant reduction in symptoms of inattention and hyperactivity-impulsivity on the SNAP-IV scale (p<0.001), improved sleep quality (p=0.002), and increased reaction speed in the Go/No-Go task (p=0.001—0.033) were observed. A trend towards improved performance on the intelligence test (Raven’s Progressive Matrices, p=0.067—0.077) was noted. The preliminary data obtained at this study indicate the potential efficacy of Miladean in correcting cognitive and behavioral impairments in children across various diagnostic categories and justify conducting further double-blind, placebo-controlled studies.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 88-95
Cogitum in the treatment of mental disorders in childhood
The development of many mental disorders, including schizophrenia and autism, is associated with early organic damage to the central nervous system. Moreover, even in severe cases of schizophrenia and autism spectrum disorders, endogenous factors are the main cause of the disease, and organic lesions serve as triggers or aggravating circumstances. The drug Cogitum, a synthetic analog of N-acetylaspartate, is actively used in pediatric neuropsychiatry. This aspartic acid derivative, is critically important for brain development, hormonal regulation, and steroidogenesis. It is present in high concentrations in the brains of embryos and newborns, participating in key metabolic processes. The review analyzes current research on the use of Cognition in various mental disorders — ADHD, delayed speech development, asthenic conditions, autistic and schizophrenic spectrum disorders. According to the results of the studies presented in this article, the drug Cogitum has shown its effectiveness and safety for children. It is concluded that further studies of the therapeutic potential of Cogitum in various diseases are necessary to expand the indications for use.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 88-95
Cogitum in the treatment of mental disorders in childhood
The development of many mental disorders, including schizophrenia and autism, is associated with early organic damage to the central nervous system. Moreover, even in severe cases of schizophrenia and autism spectrum disorders, endogenous factors are the main cause of the disease, and organic lesions serve as triggers or aggravating circumstances. The drug Cogitum, a synthetic analog of N-acetylaspartate, is actively used in pediatric neuropsychiatry. This aspartic acid derivative, is critically important for brain development, hormonal regulation, and steroidogenesis. It is present in high concentrations in the brains of embryos and newborns, participating in key metabolic processes. The review analyzes current research on the use of Cognition in various mental disorders — ADHD, delayed speech development, asthenic conditions, autistic and schizophrenic spectrum disorders. According to the results of the studies presented in this article, the drug Cogitum has shown its effectiveness and safety for children. It is concluded that further studies of the therapeutic potential of Cogitum in various diseases are necessary to expand the indications for use.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 38-47
Aripiprazole in the treatment of psychiatric disorders in childhood
For child psychiatry, the priority task is not only the relief of psychopathological symptoms, but also the preservation and restoration of cognitive functioning. Drugs that are active against a wide range of psychopathological disorders, including the productive, negative, affective, and cognitive domains, while having a favorable tolerance profile, will be the most suitable for solving this problem. The unique therapeutic profile of aripiprazole meets all these requirements. The efficacy and tolerability of Aripiprazole in children and adolescents have been demonstrated in many open-label clinical trials, which served as the basis for the drug’s approval by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Aripiprazole is also included in national clinical guidelines for the treatment of autistic disorders. The high frequency of prescribing aripiprazole in childhood is due not only to its positive effect on negative, cognitive and affective symptoms, but also to its good general tolerance, low probability of developing extrapyramidal symptoms, absence of adverse effects on body weight and metabolic parameters (lipid profile, tissue sensitivity to insulin, etc.).
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 38-47
Aripiprazole in the treatment of psychiatric disorders in childhood
For child psychiatry, the priority task is not only the relief of psychopathological symptoms, but also the preservation and restoration of cognitive functioning. Drugs that are active against a wide range of psychopathological disorders, including the productive, negative, affective, and cognitive domains, while having a favorable tolerance profile, will be the most suitable for solving this problem. The unique therapeutic profile of aripiprazole meets all these requirements. The efficacy and tolerability of Aripiprazole in children and adolescents have been demonstrated in many open-label clinical trials, which served as the basis for the drug’s approval by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Aripiprazole is also included in national clinical guidelines for the treatment of autistic disorders. The high frequency of prescribing aripiprazole in childhood is due not only to its positive effect on negative, cognitive and affective symptoms, but also to its good general tolerance, low probability of developing extrapyramidal symptoms, absence of adverse effects on body weight and metabolic parameters (lipid profile, tissue sensitivity to insulin, etc.).
- Open Access
- 8 January 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (5) , 38-48
Complement System Marker for Assessing the Effectiveness of Therapy in Patients with Autism Spectrum Disorder and Childhood Schizophrenia
Background: assessment of the effectiveness of antipsychotic therapy is generally based on the knowledge, experience of the psychiatrist, and psychometric scales. However, all changes in a person’s mental state can be both a consequence and a cause of changes in biochemical processes, one of which is the complement system (CS). In addition to the fact that CS is the most important factor in innate immunity, its proteins, especially C3, are ubiquitous and directly involved in organismal and cellular homeostasis. CS includes its connection with coagulation, which compensates for the lack of activation potential of the cascade proteolytic complement system, as the first link of immunity. The deficiency is associated with excessive consumption of CS proteins in pathologically altered processes, which also determine mental pathologies. A change in the level of this connection allows one to determine changes in the overall level of homeostasis, for example, as a result of treatment. A new marker for assessing the level of coagulation-complement coupling, equal to the difference in the functional activity of CS in plasma and serum (d), may increase the reliability of assessing the effectiveness of therapy. Objective: justification for the use of this marker of the complement system in combination with mental state assessments on psychometric scales and electroencephalography results to analyze the effectiveness of therapy for patients with autism and schizophrenia aged 8–14 years. Patients and Methods: the study included 7 patients aged 8 to 14 years (10 ± 2.2) with a diagnosis “Childhood autism, F84.0 (ICD-10)” and 11 patients aged 11 to 14 years (13 ± 1.4) with a diagnosis “Schizophrenia, F20 (ICD-10)”. The assessment of the condition before and after treatment was carried out using the following scales: for patients with autism — CARS (Childhood Autism Rating Scale), BFCRS (Bush–Francis Catatonia Rating Scale), CGI-S (General Clinical Severity Scale); for patients with schizophrenia — PANSS (Positive and Negative Syndrome Scale) and CGI-S. A neurophysiological study of all patients was carried out with spectral analysis and topographic mapping using the NeuroKM computer system (Russia). A calculated parameter equal to the difference (d) of the functional activity of the complement system (faCS) in plasma and serum was used as a biological marker of CS. FaCS was assessed using the method on the ciliates Tetrahymena pyriformis and the Biolat device. Results: in 14 out of 18 patients, positive changes in mental state were observed, which corresponded to positive changes in marker d, as well as positive changes in ratings on scales and EEG results, in accordance with all assessments, 14 out of 18 patients from both groups showed positive changes in their condition, in 3 patients resistance to psychopharmacotherapy and minimal positive dynamics of the condition were noted; the marker of the complement system in these patients decreased slightly upon discharge; in one patient assessments of the biological marker and scales were contradictory. Conclusion: in most patients (14 out of 18 people), the selected therapy was effective, and the new candidate marker d of the complement system changed in the same direction (its normalization was noted) with clinical symptoms and neurophysiological parameters. The results of the study suggest that the candidate marker d reflects changes in the patients’ conditions as a result of treatment.
- 8 January 2025
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (5) , 38-48
Open AccessComplement System Marker for Assessing the Effectiveness of Therapy in Patients with Autism Spectrum Disorder and Childhood Schizophrenia
Background: assessment of the effectiveness of antipsychotic therapy is generally based on the knowledge, experience of the psychiatrist, and psychometric scales. However, all changes in a person’s mental state can be both a consequence and a cause of changes in biochemical processes, one of which is the complement system (CS). In addition to the fact that CS is the most important factor in innate immunity, its proteins, especially C3, are ubiquitous and directly involved in organismal and cellular homeostasis. CS includes its connection with coagulation, which compensates for the lack of activation potential of the cascade proteolytic complement system, as the first link of immunity. The deficiency is associated with excessive consumption of CS proteins in pathologically altered processes, which also determine mental pathologies. A change in the level of this connection allows one to determine changes in the overall level of homeostasis, for example, as a result of treatment. A new marker for assessing the level of coagulation-complement coupling, equal to the difference in the functional activity of CS in plasma and serum (d), may increase the reliability of assessing the effectiveness of therapy. Objective: justification for the use of this marker of the complement system in combination with mental state assessments on psychometric scales and electroencephalography results to analyze the effectiveness of therapy for patients with autism and schizophrenia aged 8–14 years. Patients and Methods: the study included 7 patients aged 8 to 14 years (10 ± 2.2) with a diagnosis “Childhood autism, F84.0 (ICD-10)” and 11 patients aged 11 to 14 years (13 ± 1.4) with a diagnosis “Schizophrenia, F20 (ICD-10)”. The assessment of the condition before and after treatment was carried out using the following scales: for patients with autism — CARS (Childhood Autism Rating Scale), BFCRS (Bush–Francis Catatonia Rating Scale), CGI-S (General Clinical Severity Scale); for patients with schizophrenia — PANSS (Positive and Negative Syndrome Scale) and CGI-S. A neurophysiological study of all patients was carried out with spectral analysis and topographic mapping using the NeuroKM computer system (Russia). A calculated parameter equal to the difference (d) of the functional activity of the complement system (faCS) in plasma and serum was used as a biological marker of CS. FaCS was assessed using the method on the ciliates Tetrahymena pyriformis and the Biolat device. Results: in 14 out of 18 patients, positive changes in mental state were observed, which corresponded to positive changes in marker d, as well as positive changes in ratings on scales and EEG results, in accordance with all assessments, 14 out of 18 patients from both groups showed positive changes in their condition, in 3 patients resistance to psychopharmacotherapy and minimal positive dynamics of the condition were noted; the marker of the complement system in these patients decreased slightly upon discharge; in one patient assessments of the biological marker and scales were contradictory. Conclusion: in most patients (14 out of 18 people), the selected therapy was effective, and the new candidate marker d of the complement system changed in the same direction (its normalization was noted) with clinical symptoms and neurophysiological parameters. The results of the study suggest that the candidate marker d reflects changes in the patients’ conditions as a result of treatment.
- 27 December 2024
- Published by Mental Health Research Institute in Сибирский вестник психиатрии и наркологии
- No. 4(125)
Клинические особенности депрессивных расстройств в детском и подростковом возрастах
- 27 December 2024
- Published by Mental Health Research Institute in Сибирский вестник психиатрии и наркологии
- No. 4(125)
Клинические особенности депрессивных расстройств в детском и подростковом возрастах
- Open Access
- 24 July 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (3) , 24-33
Mood Disorders in Schizotypal Disorder with Leading Syndrome of Eating Disorders
Background: сoverage of the problem of mood disorders in patients with schizotypal disorder with leading eating disorders (EDs), in childhood and adolescence is relevant. However, concomitant disorders in eating disorder in childhood and adolescence and their dynamics have not been sufficiently studied. The aim: to study the clinical and psychopathological structure of mood disorders in patients with schizotypal disorder and eating disorders leading in the clinical picture. Patients and methods: the study included 50 patients (9 boys, 41 girls), aged 7 to 16 years. Inclusion criteria: 1) schizotypal disorder; 2) eating disorders; 3) mood disorders. Research methods: clinical-psychopathological, psychometric (HDRS, PANSS), follow-up, somatic observation. Results: in patients with schizotypal and mood disorders, the following variants of eating disorder were observed: anorexia nervosa (AN — first type), anorexia nervosa with dominance of bulimia (ANB — second type), anorexia nervosa with dominance of bulimia and vomitomania (ANB + B — third type). Mood disorders in the first type of eating disorder were characterized by a pronounced depressive triad, suicidal thoughts and stupor at the cachectic stage of the disease. Mood disorders in the second type of eating disorder were characterized by a mixed affective state: short unproductive mania, ideas of dysmorphophobia, ideas of attitude, followed by a prolonged depressive state with senesto-hypochondriacal disorders, asthenia, and an increase in cognitive impairment. Mood disorders in the third type of eating disorder were characterized by the presence, of pronounced delusional and dysmorphophobic disorders and ideas of attitude, psychopathic behavior, depersonalization-derealization disorders, asthenia and cognitive impairment. Affective pathology in schizotypal disorder with eating disorder, as well as body dysmorphic syndrome, persisted for a long time. The most severe course was observed in the third group of patients (NANB + B), which was due to a significant proportion of psychotic disorders in the structure of the syndrome and somatic complications due to vomiting behavior. Conclusions: patients with schizotypal disorder with leading symptoms of eating disorder and mood disorders require an integrated approach to therapy, including somatic and psychopharmacological treatment.
- 24 July 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (3) , 24-33
Open AccessMood Disorders in Schizotypal Disorder with Leading Syndrome of Eating Disorders
Background: сoverage of the problem of mood disorders in patients with schizotypal disorder with leading eating disorders (EDs), in childhood and adolescence is relevant. However, concomitant disorders in eating disorder in childhood and adolescence and their dynamics have not been sufficiently studied. The aim: to study the clinical and psychopathological structure of mood disorders in patients with schizotypal disorder and eating disorders leading in the clinical picture. Patients and methods: the study included 50 patients (9 boys, 41 girls), aged 7 to 16 years. Inclusion criteria: 1) schizotypal disorder; 2) eating disorders; 3) mood disorders. Research methods: clinical-psychopathological, psychometric (HDRS, PANSS), follow-up, somatic observation. Results: in patients with schizotypal and mood disorders, the following variants of eating disorder were observed: anorexia nervosa (AN — first type), anorexia nervosa with dominance of bulimia (ANB — second type), anorexia nervosa with dominance of bulimia and vomitomania (ANB + B — third type). Mood disorders in the first type of eating disorder were characterized by a pronounced depressive triad, suicidal thoughts and stupor at the cachectic stage of the disease. Mood disorders in the second type of eating disorder were characterized by a mixed affective state: short unproductive mania, ideas of dysmorphophobia, ideas of attitude, followed by a prolonged depressive state with senesto-hypochondriacal disorders, asthenia, and an increase in cognitive impairment. Mood disorders in the third type of eating disorder were characterized by the presence, of pronounced delusional and dysmorphophobic disorders and ideas of attitude, psychopathic behavior, depersonalization-derealization disorders, asthenia and cognitive impairment. Affective pathology in schizotypal disorder with eating disorder, as well as body dysmorphic syndrome, persisted for a long time. The most severe course was observed in the third group of patients (NANB + B), which was due to a significant proportion of psychotic disorders in the structure of the syndrome and somatic complications due to vomiting behavior. Conclusions: patients with schizotypal disorder with leading symptoms of eating disorder and mood disorders require an integrated approach to therapy, including somatic and psychopharmacological treatment.